ArticleFrontiers in pharmacology2022
Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Developing a Core Outcome Set for Herpes Zoster-Associated Neuralgia in Clinical Trials of Traditional Chinese Medicine: A Study Protocol.Journal of multidisciplinary healthcare · 2026Article
- Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers.Frontiers in endocrinology · 2026Review
- Regulating Lipid Metabolism in Gout: A New Perspective with Therapeutic Potential.International journal of general medicine · 2024Review
- Development of CORE-CM core outcome domain sets for trials of Chinese medicine for lumbar spinal stenosis.BMJ open · 2023Article
- Development of a core outcome set for cardiovascular diabetology: a methodological framework.Frontiers in endocrinology · 2023Article
- Development of a Core Outcome Set for Randomised Controlled Trials of Nursing Education: A Methodological Framework.Journal of nursing management · 2023Article
- Mechanism of rhubarb in the treatment of hyperlipidemia: A recent review.Open medicine (Warsaw, Poland) · 2023Review
- Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set.Evidence-based complementary and alternative medicine : eCAM · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.